Revolution Medicines' Daraxonrasib Trial Reports 13.2-Month Median Survival in Pancreatic Cancer Patients
Revolution Medicines announced results from a late-stage trial of its experimental oral drug daraxonrasib for pancreatic cancer patients. Patients receiving daraxonrasib had a median overall survival of 13.2 months, compared to 6.7 months for those on standard intravenous cytotoxic chemotherapy. The drug is administered as a once-daily pill.
France 24# Revolution Medicines Announces Positive Late-Stage Trial Results for Daraxonrasib Revolution Medicines announced on Monday the results of a late-stage trial for its experimental oral drug daraxonrasib in pancreatic cancer patients. The trial involved patients receiving daraxonrasib, which is administered as a once-daily pill. 2 months.
Trial Compares Daraxonrasib to Standard Chemotherapy The trial compared daraxonrasib to intravenous cytotoxic chemotherapy, the standard of care for pancreatic cancer patients.
7 months. Revolution Medicines conducted the late-stage trial, as reported by the company.
Background on Daraxonrasib and Pancreatic Cancer Treatment Daraxonrasib targets pancreatic cancer through oral administration.
The trial focused on patients with pancreatic cancer, providing data on survival outcomes. Intravenous cytotoxic chemotherapy remains the established treatment option for such patients.
Announcement Details and Implications Revolution Medicines released the trial results on Monday.
The data indicate a difference in median overall survival between the two treatment groups. The company provided the details via its official channels.
Story Timeline
3 events- 2026-04-14
Revolution Medicines announced the late-stage trial results for daraxonrasib.
1 sourceRevolution Medicines - Prior to 2026-04-14
Revolution Medicines conducted the late-stage trial of daraxonrasib for pancreatic cancer patients.
1 sourceRevolution Medicines - Ongoing
Intravenous cytotoxic chemotherapy serves as the standard of care for pancreatic cancer patients.
1 sourceunattributed
Potential Impact
- 01
Improved survival outcomes for patients eligible for daraxonrasib therapy.
- 02
Potential shift in pancreatic cancer treatment options if daraxonrasib gains approval.
- 03
Increased focus on oral therapies over intravenous chemotherapy standards.
Transparency Panel
Related Stories
StatFDA Sends Reminder Letters to Over 2,200 Companies and Researchers on Clinical Trial Reporting
The Food and Drug Administration sent reminder letters to more than 2,200 companies and researchers, informing them of the requirement to report clinical trial results to a federal database or face fines. The letters target entities associated with over 3,000 registered trials, s…
Sebastian Ballard / Wikimedia (CC BY-SA 2.0)Hospital Admissions for Spider Bites Increase in England Over Past Decade
NHS figures show hospital admissions linked to spider bites in England rose from 47 in 2015 to 100 in 2025. Experts attribute the trend to the growing population of noble false widow spiders. The spiders are not aggressive and have not caused serious illness or death, though bite…
StatSTAT Publishes Reader Responses on Nutrition Education and Emergency Room Challenges in Healthcare
STAT News featured letters to the editor responding to articles on nutrition education in medical schools and emergency room conditions. Contributors addressed social determinants of health, the need for interdisciplinary collaboration, and risks to vulnerable patients in ER hall…